INCY vs REGN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

REGN is the larger of the two ($99.94B market cap): the incumbent the market prices for continued execution (13.79x forward earnings, beta 0.09). INCY is the smaller challenger ($24.43B), priced similarly on forward earnings (13.84x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

INCY vs REGN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricINCYREGNWhat it tells you
Market cap$24.43B$99.94BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E13.8413.79Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E61.1421.35Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.780.09Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range71% of range98% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book4.332.89How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how INCY and REGN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. INCY and REGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined INCY and REGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Incyte Corporation (INCY) do?

Incyte Corporation is a Wilmington, Delaware based biopharmaceutical company that discovers, develops, and commercializes drugs in oncology, hematology, and dermatology. Its flagship product is Jakafi (ruxolitinib), an oral JAK inhibitor approved for myelofibrosis, polycythemia vera, and graft-versus-host disease, which still generates the largest share of company revenue (roughly $758 million in Q1 2026, up about 7%). Beyond Jakafi, Incyte sells the topical cream Opzelura (ruxolitinib) for atopic dermatitis and vitiligo, plus a widening hematology and oncology lineup including Monjuvi/Minjuvi, Niktimvo, and Zynyz, and it funds a broad clinical pipeline of oncology and immunology candidates. In September 2026 the FDA approved Atebrioz (zilurgisertib), an Incyte-discovered ALK2 inhibitor, for fibrodysplasia ossificans progressiva; Incyte licensed US commercialization to Mirum Pharmaceuticals.

Full INCY guide

What does Regeneron Pharmaceuticals (REGN) do?

Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base. Total revenue then stepped up to about $4.29 billion in Q2 2026, up roughly 17% year over year, taking trailing twelve-month revenue to about $15.5 billion and net income to about $4.3 billion.

Full REGN guide

INCY vs REGN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • INCY drivers: Jakafi franchise still growing near-term; Non-Jakafi revenue diversification.
  • REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is revenue concentration: Jakafi still drives the majority of sales and faces US loss of exclusivity in December 2028, after which generic ruxolitinib is expected to erode the franchise. For REGN, the clearest risk is Eylea biosimilar erosion.

INCY or REGN: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick INCY if you believe its drivers more; REGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the INCY and REGN guides.

INCY vs REGN: the full fundamentals

INCY. Incyte trades at about 14.5x trailing and 13x forward earnings, a modest multiple for a profitable biopharma growing revenue near 38% in its latest quarter, which reflects investor caution about the 2028 Jakafi cliff. Near-term reported earnings will be noisy, with consensus calling for a Q3 2026 loss and full-year 2026 EPS of about $3.12 before a rebound toward $8.68 in 2027. The 24 covering analysts lean buy, with a mean target near $130 against a close of about $114 on October 16, 2026.

REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron has beaten EPS estimates in each of the last four quarters, most sharply in Q2 2026 (about $14.29 against $10.21), and the shares rose about 18% over three months to roughly $794, up about 40% over a year. Consensus for Q3 2026, due October 30, sits near $16.06 of EPS on about $4.54 billion of revenue, and the ~13x forward P/E reflects the market weighing strong Dupixent growth against Eylea biosimilar erosion expected to accelerate around the fourth quarter of 2026.

Headline figures (approximate, October 2026): INCY shows revenue (ttm) ~$5.8B, q2 2026 revenue ~$1.67B (up ~38% YoY), margins (operating / net) ~42% / ~28%, net income (ttm) ~$1.6B (EPS ~$7.85); REGN shows total revenue (ttm) ~$15.5 billion, q2 2026 total revenue ~$4.29 billion (up ~17% YoY), q2 2026 eps vs estimate ~$14.29 vs ~$10.21, net income (ttm) ~$4.3 billion (~28% net margin).

The bottom line: INCY vs REGN

INCY and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined INCY and REGN exposure against your real portfolio. It is not an investment adviser.

Wondering how INCY or REGN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Investing in Incyte Corporation with AI

Connect the broker you already use and ask Walnut's AI how INCY fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

FAQ

What is the difference between INCY and REGN?

+

Incyte Corporation is a Wilmington, Delaware based biopharmaceutical company that discovers, develops, and commercializes drugs in oncology, hematology, and dermatology. Regeneron makes money primarily through two large franchises. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is INCY or REGN the better stock?

+

Neither is universally better. REGN is the larger incumbent; INCY is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, INCY or REGN?

+

On forward P/E (as of November 2026), INCY trades at 13.84x and REGN at 13.79x, so REGN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both INCY and REGN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of INCY vs REGN?

+

INCY: The dominant risk is revenue concentration: Jakafi still drives the majority of sales and faces US loss of exclusivity in December 2028, after which generic ruxolitinib is expected to erode the franchise. Pipeline and launch execution carry real uncertainty, as shown by the FDA's rejection of the once-daily extended-release Jakafi formulation, and clinical trials can fail at any stage. Reported earnings can also swing sharply: analysts expect a loss of about $3.84 per share for Q3 2026 even with revenue near $1.48 billion, and full-year 2026 EPS consensus of about $3.12 is well below the $7.85 trailing figure. Full-year revenue guidance given with Q2 also came in below analyst expectations. Competition is intensifying from larger peers with deeper resources in both oncology (Bristol Myers Squibb, Novartis, AbbVie) and inflammation/dermatology (AbbVie's Rinvoq, Eli Lilly's Olumiant, Pfizer, Regeneron). Morningstar has downgraded Incyte's economic moat toward none, citing the looming patent loss. If non-Jakafi revenue does not scale to the $3 billion to $4 billion goal in time, the company could face a revenue gap late this decade. REGN: The clearest risk is Eylea biosimilar erosion. Amgen's Pavblu launched in late 2024 and pressured sales, and settlements clear paths for Sandoz, and Alvotech and Teva, to launch competing copies in the U.S. around the fourth quarter of 2026, with erosion expected to accelerate. Eylea HD and Dupixent growth are the offsets, but the timing gap matters. The business is also concentrated in a few franchises, so a single setback in Dupixent or a major pipeline failure would weigh heavily, and the collaboration structure with Sanofi means Regeneron does not control all of its largest product's economics.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell INCY or REGN; figures are approximate and dated (as of November 2026). Verify current data before investing.